Immune-related Bell’s palsy in melanoma patients treated with immune checkpoint inhibitors

xlomafota13 shared this article with you from Inoreader Immune-related Bell's palsy in melanoma patients treated with immune checkpoint inhibitors Via Melanoma Research - Published Ahead-of-Print Immune-checkpoint inhibitors (ICIs) exposed the oncology community to novel immune-related adverse events (irAEs). Here, we report on a retrospective analysis of patients with melanoma who developed an ICI-related, unilateral, acute and peripheral facial nerve paralysis (Bell's palsy).We retrospectively reviewed a ll the cases of ICI-related Bell's palsy in patients with melanoma treated at our institution from January 2015 to January 2020. A total of five cases of ICI-related Bell's palsy were identified. Median age was 63 years. Median time-to-onset of Bell's palsy from ICIs initiation was 15 weeks. Four patients were treated with prednisone alone, whereas one patient was treated with prednisone plus valaciclovir. All the patients completely recovered from Bell's palsy without neurological sequelae. In melanoma patients treated with ICIs, Bell's palsy is a rare, neurologic irAE with a favorable outcome following administration of oral corticosteroids. Received 12 November 2020 Accepted 29 December 2020 Correspondence to Carolina Cimminiello, MD, Department of Medical Oncology and Hematology, Melanoma Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian, 1 – 20133, Milan, Italy, Tel: +39 02 2390 3823; e-mail: carolina.cimminiello@istitutotumori.mi.it Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.